Literature DB >> 20737568

Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area.

Jeffrey W Allen1, Aamer Farooq, Thomas F O'Brien, Raymond U Osarogiagbon.   

Abstract

BACKGROUND: Curative treatment of early stage nonsmall cell lung cancer (NSCLC) requires good quality surgical resection (GQR). The degree of compliance with national recommendations for GQR is poorly defined. We sought to quantitatively define the degree of compliance in a consecutive series of NSCLC resections.
METHODS: Medical records of patients who underwent curative-intent resection for NSCLC in the Memphis, TN metropolitan area from January 1, 2004 to December 31, 2007 were retrospectively reviewed (N = 746 patients). GQR criteria were obtained from the National Comprehensive Cancer Network (NCCN), the RADIANT adjuvant study of erlotinib, and the American College of Surgeons Oncology Group (ACOSOG) Z0030 study. Factors associated with or without achievement of GQR were evaluated. Categorical variables were compared using chi-square or Fisher exact test, and survival curves by the log-rank test.
RESULTS: Twenty-three and one-half percent of patients met GQR criteria as established by RADIANT, 8.2% by NCCN, and 0.9% by ACOSOG. The most common limiting factor in achieving GQR was inadequate lymph node sampling. The only patient factor associated with GQR was race (African-Americans were more likely than Caucasians to have GQR per RADIANT and NCCN criteria [P = .022 and P = .0489, respectively]). There was no significant survival difference between GQR and non-GQR patients.
CONCLUSIONS: The vast majority of curative-intent resections did not achieve GQR standards. The greatest deficit is in surgical sampling of mediastinal (Level 2) lymph nodes, but evaluation of Level 1 lymph nodes is also suboptimal. Interventions are needed to improve current surgical practices and achieve minimum standards for accurate staging, prognostication, and eligibility for clinical trials.
© 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20737568     DOI: 10.1002/cncr.25334

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Response to editorial titled 'Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection'.

Authors:  Raymond U Osarogiagbon; Laura E Miller; Christopher G Wang; Robert A Ramirez
Journal:  Transl Lung Cancer Res       Date:  2013-04

2.  Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection.

Authors:  Christina Brzezniak; Giuseppe Giaccone
Journal:  Transl Lung Cancer Res       Date:  2012-12

Review 3.  Towards optimal pathologic staging of resectable non-small cell lung cancer.

Authors:  Raymond U Osarogiagbon; Gail E Darling
Journal:  Transl Lung Cancer Res       Date:  2013-10

4.  Improved lymph node staging in early-stage lung cancer in the national cancer database: commentary.

Authors:  Hisashi Saji; Koji Kojima; Haruhiko Nakamura
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

5.  Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM.

Authors:  Raymond U Osarogiagbon
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

6.  Size and histologic characteristics of lymph node material retrieved from tissue discarded after routine pathologic examination of lung cancer resection specimens.

Authors:  Raymond U Osarogiagbon; Robert A Ramirez; Christopher G Wang; Laura E Miller; Laura McHugh; Courtney A Adair; Matthew P Smeltzer; Xinhua Yu; Allen Berry
Journal:  Ann Diagn Pathol       Date:  2014-02-10       Impact factor: 2.090

7.  Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer.

Authors:  Meredith A Ray; Nicholas R Faris; Matthew P Smeltzer; Carrie Fehnel; Cheryl Houston-Harris; Paul Levy; Lynn Wiggins; Vishal Sachdev; Todd Robbins; David Spencer; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2018-03-11       Impact factor: 4.330

Review 8.  Measuring improvement in populations: implementing and evaluating successful change in lung cancer care.

Authors:  Xinhua Yu; Lisa M Klesges; Mathew P Smeltzer; Raymond U Osarogiagbon
Journal:  Transl Lung Cancer Res       Date:  2015-08

9.  Improving the pathologic evaluation of lung cancer resection specimens.

Authors:  Raymond U Osarogiagbon; Holly L Hilsenbeck; Elizabeth W Sales; Allen Berry; Robert W Jarrett; Christopher S Giampapa; Clara N Finch-Cruz; David Spencer
Journal:  Transl Lung Cancer Res       Date:  2015-08

10.  Quality gaps and comparative effectiveness in lung cancer staging and diagnosis.

Authors:  David E Ost; Jiangong Niu; Linda S Elting; Thomas A Buchholz; Sharon H Giordano
Journal:  Chest       Date:  2014-02       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.